Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 5/20 | 0.41 |
| ▸ | MET | P08581 | 9/20 | 0.41 |
| ▸ | MST1R | Q04912 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | HGF | P14210 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20770860 | 0.86 | ENPP3 (0.53) | FLT3METKDRBTK | |
| SCHEMBL25681687 | 0.85 | MET (0.46) | FLT3KITMETMST1RKDR | |
| SCHEMBL20782586 | 0.83 | ENPP1 (0.54) | FLT3KITMETBTK | |
| SCHEMBL30446173 | 0.83 | ENPP1 (0.54) | FLT3KITMETBTK | |
| SCHEMBL22407332 | 0.83 | ENPP3 (0.50) | METPDGFRAKMT2A | |
| SCHEMBL22407456 | 0.83 | KIT (0.61) | KITKDRKMT2A | |
| Methane SCHEMBL28438541 | 0.82 | ENPP3 (0.49) | METPDGFRAKMT2A | |
| SCHEMBL22407561 | 0.82 | ENPP3 (0.47) | METMST1RKDRHGF | |
| SCHEMBL22407611 | 0.81 | ENPP1 (0.48) | MET | |
| SCHEMBL22407379 | 0.79 | ENPP3 (0.53) | FLT3METKDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | FLT3 916/4885KIT 4057/4885MET 3803/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | FLT3 916/4885KIT 4057/4885MET 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.